Proton pump inhibitor-therapy refractory gastro-oesophageal reflux disease patients, who are they? [2]

Gut

Volumn 56, Issue 4, 2007, Pages 593-594

  Bredenoord, Albert J ^a   Dent, John ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ACID SECRETION; DRUG EFFICACY; DRUG MEGADOSE; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYMPTOM;

ANTI-ULCER AGENTS; DRUG RESISTANCE; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS; TREATMENT FAILURE;

EID: 34147214332     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.115287     Document Type: Letter

References (4)

1. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicenter study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-1402.
2. Heading RC, Bardhan KD, Sander P, et al. Application of the complete remission concept: many patients with GERD are incompletely treated by a standard proton pump inhibitor (PPI) regime. Gut 2006;55(suppl 5):A62.
3. Marrero JM, de Caestecker JS, Maxwell JD. Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. Gut 1994;35:447-450.
4. Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17:243-251.